Assessment of Racial/Ethnic and Income Disparities in the Prescription of Opioids and Other Controlled Medications in California

Joseph Friedman, MPH; David Kim, MD; Todd Schneberk, MD, MS; Philippe Bourgois, PhD; Michael Shin, PhD; Aaron Celious, PhD; David L. Schriger, MD, MPH

**IMPORTANCE** Most drug epidemics in the United States have disproportionately affected nonwhite communities. Notably, the current opioid epidemic is heavily concentrated among low-income white communities, and the roots of this racial/ethnic phenomenon have not been adequately explained.

**OBJECTIVE** To examine the degree to which differential exposure to opioids via the health care system by race/ethnicity and income could be driving the observed social gradient of the current opioid epidemic, as well as to compare the trends in the prevalence of prescription opioids with those observed for stimulants and benzodiazepines.

**DESIGN, SETTING, AND PARTICIPANTS** This population-based study used 2011 through 2015 records from California's prescription drug monitoring program (Controlled Substance Utilization Review and Evaluation System), which longitudinally tracks all patients receiving controlled substance prescriptions in the state and contained unique records for 29.7 million individuals who received such a prescription from 2011 to 2015. Data were analyzed between January and May 2018.

**EXPOSURES** A total of 1760 zip code tabulation areas (ZCTAs) in California, with associated racial/ethnic composition and per capita income.

**MAIN OUTCOMES AND MEASURES** The percentage of individuals receiving at least 1 prescription each year was calculated for opioids, benzodiazepines, and stimulants.

**RESULTS** A nearly 300% difference in opioid prescription prevalence across the race/ethnicity-income gradient was observed in California, with 44.2% of adults in the quintile of ZCTAs with the lowest-income/highest proportion–white population receiving at least 1 opioid prescription each year compared with 16.1% in the quintile with the highest-income/lowest proportion–white population and 23.6% of all individuals 15 years or older. Stimulant prescriptions were highly concentrated in mostly white high-income areas, with a prevalence of 3.8% among individuals in the quintile with the highest-income/highest proportion–white population and a prevalence of 0.6% in the quintile with the lowest-income/lowest proportion–white population. Benzodiazepine prescriptions did not have an income gradient but were concentrated in mostly white areas, with 15.7% of adults in the quintile of ZCTAs with the highest proportion–white population receiving at least 1 prescription each year compared with 7.0% among the quintile with the lowest proportion–white population.

**CONCLUSIONS AND RELEVANCE** The race/ethnicity and income pattern of opioid overdoses mirrored prescription rates, suggesting that differential exposure to opioids via the health care system may have induced the large, observed racial/ethnic gradient in the opioid epidemic. Across drug categories, controlled medications were much more likely to be prescribed to individuals living in majority-white areas. These discrepancies may have shielded nonwhite communities from the brunt of the prescription opioid epidemic but also represent disparities in treatment and access to all medications.

Published online February 11, 2019.

© 2019 American Medical Association. All rights reserved.
A salient feature of the current opioid epidemic is that it is heavily concentrated among low-income white communities.1-2 This feature is unique because most previous drug epidemics in the United States have disproportionately affected nonwhite communities.3 Globally, most epidemics occur in social minority groups.4 Therefore, the concentration of this epidemic in a racial/ethnic majority group is epidemiologically noteworthy, and it speaks to the unique social context of the current opioid crisis. The roots of this atypical racial/ethnic phenomenon have not been adequately explained in the existing literature.

The opioid epidemic has been described as a “disease of despair” in public health literature, linked to poverty and lack of economic opportunity among increasingly downwardly mobile sectors of working class America.5-8 This theory may explain the income gradient observed in the opioid epidemic; across the racial/ethnic spectrum, higher overdose rates are observed in lower-income communities.6 However, given continued racial/ethnic disparities in income and employment status, this theory alone cannot account for the preponderance of the epidemic among white communities.9-11

The opioid epidemic has also been attributed to changes within the health care system that increased the availability of prescription opioids.5,6 Opioid consumption has risen steadily in the United States during the past 3 decades, and this period has also seen the invention of powerful synthetic opioid analogues, such as fentanyl and the extended-release oxycodone, which were rapidly marketed and widely adopted.6,12-15 Renewed attention was placed on pain management, and pain became known as the “fifth vital sign”.16 Exposure to an opioid prescription has been identified as a risk factor for long-term use, with 1% to 15% of patients continuing opioid therapy at 90 days depending on setting.17-19 The majority of individuals who are dependent on heroin now report using a prescription medication as their first opioid of abuse,20 suggesting that health care professionals played an important role in the recent surge of addiction and related overdoses. This link between the health care system and opioid addiction may provide an explanation for the observed racial/ethnic differences in the outcomes of the opioid epidemic. Racial/ethnic disparities in access to health care, as well as to pain management and opioid medications specifically,21-26 are well documented and long-standing. It is therefore possible that the inductive effect of the health care system on the opioid epidemic has impacted various racial/ethnic groups differently, effectively concentrating the epidemic among lower-income white communities.

To test this theory, we quantify the race/ethnicity-income gradient in exposure to opioids by the California health care system using Prescription Drug Monitoring Program data. We use a metric that up to this point has not been widely used to characterize the crisis: the percentage of individuals receiving an opioid prescription each year. Most previous efforts to quantify the population-level consumption of opioids have focused on total volume. For example, an analysis published by the Centers for Disease Control and Prevention (CDC) in 2013 reported a consumption of 1021.7 prescriptions for opioids per 1000 residents in Louisiana.27 It is hard to gauge the human impact of this figure because it could represent 10% of the population receiving an average of about 10 prescriptions per year, 50% of the population receiving an average of about 2 prescriptions per year, or many other distributions. Thus, in the present study, we use the simple percentage of individuals who received at least 1 prescription for an opioid each year as a clear metric of the exposure of the population to opioids by the health care system. We also calculate the same metric for stimulants and benzodiazepines to compare the race/ethnicity-income gradients observed in prescription opioids to those of other controlled substances. We use the above metrics to compare the race/ethnicity-income gradient in opioid prescription with that observed for opioid-related overdose mortality.

### Methods

We calculated the percentage of the population of California receiving a prescription for an opioid, benzodiazepine, or stimulant—the prescription prevalence rate. The numerator for each rate was the number of people receiving at least 1 prescription, and the denominator was the number of people in the population. These rates were calculated separately by age group, sex, and zip code tabulation area (ZCTA) for each year from 2011 through 2015. We obtained institutional review board exemption from UCLA (University of California, Los Angeles), which also waived the need for obtaining informed patient consent.

We obtained counts of patients receiving prescriptions using deidentified data from California’s Controlled Substance Utilization Review and Evaluation System (CURES) database, which tracks all prescriptions for the Drug Enforcement Administration-scheduled medication in California.28 Anonymized, patient-specific indicators allow for following up unique patients in a longitudinal fashion. Using National Drug Codes,29 we classified each medication as an opioid, benzodiazepine, stimulant, or other based on mapping available from the CDC,30 supplemented when necessary by physician expert knowledge. Opioid-based medications used to...
In California, 23.6% of all individuals 15 years or older received a prescription for an opioid medication each year during the study period. Opioid prescriptions were concentrated among ZCTAs with a higher proportion-white/low-income population, with a mean annual prevalence of 44.2% among...
Assessment of Racial/Ethnic and Income Disparities in the Prescription of Controlled Medications in California

Figure 2. Benzodiazepine and Stimulant Prescription Prevalences

**A** Benzodiazepine prescription prevalence

<table>
<thead>
<tr>
<th>Highest Proportion White</th>
<th>Q4</th>
<th>Q3</th>
<th>Q2</th>
<th>Q1</th>
<th>Lowest Proportion White</th>
</tr>
</thead>
<tbody>
<tr>
<td>18.6</td>
<td>15.8</td>
<td>15.8</td>
<td>14.6</td>
<td>16.2</td>
<td></td>
</tr>
<tr>
<td>10.2</td>
<td>15.4</td>
<td>13.2</td>
<td>14.0</td>
<td>14.2</td>
<td></td>
</tr>
<tr>
<td>10.7</td>
<td>12.1</td>
<td>11.6</td>
<td>11.8</td>
<td>11.2</td>
<td></td>
</tr>
<tr>
<td>10.0</td>
<td>10.1</td>
<td>9.6</td>
<td>9.2</td>
<td>8.3</td>
<td></td>
</tr>
<tr>
<td>6.5</td>
<td>7.9</td>
<td>7.2</td>
<td>6.3</td>
<td>5.9</td>
<td></td>
</tr>
</tbody>
</table>

**B** Stimulant prescription prevalence

<table>
<thead>
<tr>
<th>Highest Proportion White</th>
<th>Q4</th>
<th>Q3</th>
<th>Q2</th>
<th>Q1</th>
<th>Lowest Proportion White</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.6</td>
<td>1.3</td>
<td>1.6</td>
<td>1.8</td>
<td>3.8</td>
<td></td>
</tr>
<tr>
<td>1.3</td>
<td>1.4</td>
<td>1.6</td>
<td>2.0</td>
<td>3.1</td>
<td></td>
</tr>
<tr>
<td>1.2</td>
<td>1.4</td>
<td>1.6</td>
<td>2.0</td>
<td>2.3</td>
<td></td>
</tr>
<tr>
<td>1.0</td>
<td>1.2</td>
<td>1.4</td>
<td>1.4</td>
<td>1.6</td>
<td></td>
</tr>
<tr>
<td>0.6</td>
<td>0.8</td>
<td>0.8</td>
<td>0.7</td>
<td>0.9</td>
<td></td>
</tr>
</tbody>
</table>

Annual prevalence of receiving at least 1 prescription for a benzodiazepine (A) or a stimulant (B). Both figures represent the entire state of California, showing quartiles (Qs) of mean annual rates during the 2011 through 2015 study period.

**Discussion**

Whereas most epidemics predominate within social minority groups and previous US drug epidemics have typically been concentrated in nonwhite communities, the current opioid crisis is largely found among lower-income and majority-white communities. Our analysis suggests that, at least in California, an important determinant of this phenomenon may be that white individuals have a higher level of exposure than nonwhite individuals to opioid prescriptions on a per capita basis through the health care system. Across the income spectrum of the state of California, and especially within the lowest-income quintile of ZCTAs, we observed much higher rates of opioid prescription in the areas with the highest proportion-white population.

The vast majority of individuals receiving opioid prescriptions in California are not dependent opioid users. As shown in previously published work,38 the bulk of those individuals are receiving sporadic prescriptions for small quantities of opioids, representing short-term treatment courses for acute conditions. Only a tiny fraction of opioid users show behavior consistent with dangerous patterns even though they do consume a large share of the total volume of prescribed opioids. The race/ethnicity-income pattern observed in the present...
study therefore represents both a difference in the negative consequences of opioid addiction and also a noteworthy social trend in the general use patterns of opioids for acute, medically appropriate purposes. The nearly 300% gradient observed across the state also reflects the nature of the health care system and its distribution of prescription opioids in California.

Important clues that help explain the observed racial/ethnic gradient in opioid prescription rates can be found in the large body of literature documenting minority disparities stemming from implicit biases and reduced access to the health care system. For instance, clinicians are more likely to prescribe opioids for pain management to white patients than to racial/ethnic minority patients presenting with the same symptoms across numerous clinical settings and geographies.21-26,39 One foundational study showed that Hispanic patients were 2 times less likely to receive analgesics following long bone fractures than white patients, after accounting for other factors.40 Similar discrepancies in pain medication prescribing were found for black patients relative to white patients.26

Recent studies have found that health care professionals often underestimate the pain of black patients when compared with white patients and that such racial/ethnic biases in the detection of pain are seen among health care professionals who report no explicit racial/ethnic biases.25 These gaps, coupled with decreased access to the health care system for many racial/ethnic minority groups,41,42 have led several authors to suggest that there is a national crisis of insufficiently medicated pain among minority communities in the United States.3,21,23,39 In light of a similar gradient in opioid overdose deaths, these disparities in opioid prescription may have played an accidental protective role in minimizing the opioid epidemic among minority communities. Nevertheless, they also represent the undertreatment of the legitimate
medical needs of patients of color and remain an important inequity to be ameliorated.

We also observed that the concentration of prescription medications in mostly white communities is not unique to opioids. Although the trend by income level varies among drug classes, across the board, prescription medications were overwhelmingly prescribed at higher rates to patients who lived in areas with a higher proportion–white population. Prescriptions for stimulants were remarkably concentrated in ZCTAs with a higher-income/higher proportion–white population. Rates were highest among male adolescents aged 10 to 14 years (eFigure 2 in the Supplement), suggesting that the largest contribution of stimulant prescriptions is for the treatment of attention-deficit/hyperactivity disorder (ADHD). Substantial racial and ethnic disparities in the detection and subsequent treatment of ADHD have been noted in the literature, which may be reflected in the population-level pattern we observed.43-45 Benzodiazepine prescription was concentrated in the quintile of ZCTAs with the highest proportion–white population at more than double the rate observed in the quintile of ZCTAs with the lowest proportion–white population. However, little variation in benzodiazepine prescription prevalence was observed across income categories. Racial/ethnic disparities in the diagnosis and treatment of epilepsy, as well as anxiety and other mental health conditions treated with benzodiazepines, have also been previously noted and may play an important role in the overall trends observed.46,47

Granular maps of prescription prevalence rates in Los Angeles County revealed how stark social differences in the use of controlled substances are within the same city. In the high-income and mostly white neighborhoods around Beverly Hills, more than 1 of every 4 adults received a benzodiazepine prescription during the study period. In the low-income inner-city neighborhoods of Compton and Watts, that number was only 1 of every 20 adults. This 5-fold difference in the rate of a basic medical treatment between neighborhoods in the same city is unlikely to be explained by variation in the underlying need for these medications.

Limitations

This study was limited in its use of ecological-level sociodemographic information. We linked prescription prevalence to income and racial/ethnic composition at the ZCTA level. Although the 1760 ZCTAs included in the study provided a granular picture, we were unable to establish associations at the individual level. The ecological nature of the association we described limited our ability to identify mechanisms that may be at play. For example, we had no ability to determine if receiving a prescription for opioids made an individual more likely to become addicted and subsequently use heroin, or if the individuals overdosing on opioids were the same individuals receiving prescriptions for opioids. In the present analysis, we simply highlighted a similar social gradient observed between the outcomes of the opioid crisis and the level of opioid prescription by the health care system, which may represent an important driver of the epidemic.

The generalizability of the present study to the rest of the country may be affected by California’s generally low rates of controlled substance prescription relative to other states.27 The results, therefore, may not fully represent the magnitude of prescribing that we would observe in other states, although the race/ethnicity and income trends may be widely generalizable. However, California represented an apt location to study this topic because its wide range of racial/ethnic and socioeconomic diversity enabled us to study a more complete picture of the social dynamics of opioid prescription. Furthermore, given its large population size, California represents a sizable share of total prescribing in the United States.

Potential factors affecting the accuracy of our prevalence estimates included the possibility that the algorithm used by the Controlled Substance Utilization Review and Evaluation System database to track individuals over time is imperfect, leading to the same individual being listed more than once, which could inflate prevalence. The 3.7% of observations that we had to exclude due to missing data could have also resulted in a slight underestimate of prevalence (eTable in the Supplement). Our metric of opioid prescription prevalence included all opioids except those medications used to treat opioid dependence, such as methadone or buprenorphine, which may represent a limitation for interpretation. Although a small fraction of these medications may be abused, the vast majority are used for treatment of opioid dependence and were excluded from our measure of exposure to potentially addicting opioid medications.48

Conclusions

Although the opioid epidemic receives considerable attention in the medical and public health communities, the mainstream media, and even in the national political arena, race/ethnicity is seldom included in discussions about the epidemic. Previous work by the CDC illustrates substantial population-level geographic variations in prescription prevalence rates,27 but relatively few efforts have been made to explain this variation with sociodemographic data. Our results suggest that race/ethnicity and income are key factors by which variations in prescription prevalence may be understood. This study represents one of the first population-level efforts, to our knowledge, to quantify the social patterns of prescription drug use. The results provide important insights when trying to understand the prescription drug epidemic that is occurring in mostly white communities and the reported disparities in untreated pain, anxiety, and ADHD that are simultaneously found in minority communities.
Acquisition, analysis, or interpretation of data: Friedman, Schneberk, Kim, Bourgois, Celious, Schriger.

Drafting of the manuscript: Friedman, Schneberk, Schriger.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Friedman, Schneberk, Kim, Shin, Celious, Schriger.

Obtained funding: Schriger.

Administrative, technical, or material support: Friedman, Schneberk, Kim, Schriger.

Conflict of Interest Disclosures: None reported.

Funding/Support: Dr Schriger’s time on this project was supported in part by an unrestricted grant from the Korein Foundation.

Role of the Funder/Sponsor: The funder played no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

REFERENCES


© 2019 American Medical Association. All rights reserved.
The opioid overdose epidemic affects millions of Americans and their families. Nationwide polls reveal that 49% of respondents personally know someone who is or has been addicted to prescription opioid medication. In 2017, more than 49,000 people died in the United States of opioid overdoses, according to preliminary data from the Centers for Disease Control and Prevention (CDC). This crisis has spanned different phases, beginning with increased overdose deaths from prescription opioids, which then evolved to increased heroin overdose deaths, and most recently manifesting as a dramatic spike in overdose deaths from illicitly manufactured fentanyl and fentanyl analogs.

Two articles in this issue of JAMA Internal Medicine bring renewed attention to health care professionals and prescription practices as both contributors and potential solutions to the opioid overdose epidemic. Friedman et al report that the prevalence of opioid prescriptions was higher in 2011 through 2015 in mostly white, low-income zip codes in California compared with higher-income areas or areas with smaller white populations, mirroring the national race-income distribution of opioid overdoses. Their findings underscore the importance of monitoring regional prescribing trends and of targeting interventions to ensure communities at risk have the proper resources to respond to the opioid overdose epidemic. As part of the federal effort to address these areas of significance, the US Department of Health and Human Services (HHS) has declared a public health emergency and has launched a 5-point opioid strategy.

The HHS strategy includes (1) better addiction prevention, treatment, and recovery services; (2) better data; (3) better pain management; (4) better targeting of overdose reversing drugs; and (5) better research. As part of a multifaceted response, HHS has this year invested more than $2 billion in opioid-specific funding to states and communities through Substance Abuse and Mental Health Services Administration (SAMHSA) and Health Resources and Services Administration grants; provided implementation support for the CDC Guideline for Prescribing Opioids for Chronic Pain, including the enhanced integration and use of prescription drug monitoring programs; and developed a collaborative research effort through the National Institutes of Health to prevent and treat opioid misuse and opioid use disorder (OUD).

Guy et al report in this issue of JAMA Internal Medicine that the rate of opioid prescribing decreased in 2015 through 2017, although they acknowledge that current opioid prescribing is still almost three times as high as it was in 1999. The authors emphasize the importance of providing evidence-based resources to prescribers, such as the CDC Guideline to improve opioid prescribing practices. Consistent with this emphasis, HHS recently released several resources targeted to both prescribers and the communities in which they serve.

In September 2018, the Office of the Surgeon General, together with SAMHSA, released Facing Addiction in America: The Surgeon General’s Spotlight on Opioids and a digital postcard. Both resources call for a cultural shift in the way people think and talk about the opioid crisis and recommend actions that can prevent and treat opioid misuse and promote recovery.

In addition, HHS also published a comprehensive strategy document detailing 72 independent focus areas to implement the initial 5-point strategy. Finally, HHS recently published a notice in the Federal Register from the Pain Management Best Practices Inter-Agency Task Force. The notice asks for public comments to its draft recommendations to inform further guideline development, research, and education. There is some good news to report: Since January 2017, the amount of morphine milligram equivalents prescribed has declined 19.4%, the number of patients receiving buprenorphine for medication-assisted treatment has increased 21%, and monthly prescriptions for naloxone have increased 368%. And, according to the National Survey on Drug Use and Health, the number of Americans reported to be misusing pain relievers has significantly decreased.

Opioid Prescribing Trends and the Physician’s Role in Responding to the Public Health Crisis

Jerome M. Adams, MD, MPH; Brett P. Giroir, MD

The opioid overdose epidemic affects millions of Americans and their families. Nationwide polls reveal that 49% of respondents personally know someone who is or has been addicted to prescription opioid medication. In 2017, more than 49,000 people died in the United States of opioid overdoses, according to preliminary data from the Centers for Disease Control and Prevention (CDC). This crisis has spanned different phases, beginning with increased overdose deaths from prescription opioids, which then evolved to increased heroin overdose deaths, and most recently manifesting as a dramatic spike in overdose deaths from illicitly manufactured fentanyl and fentanyl analogs.

Two articles in this issue of JAMA Internal Medicine bring renewed attention to health care professionals and prescription practices as both contributors and potential solutions to the opioid overdose epidemic. Friedman et al report that the prevalence of opioid prescriptions was higher in 2011 through 2015 in mostly white, low-income zip codes in California compared with higher-income areas or areas with smaller white populations, mirroring the national race-income distribution of opioid overdoses. Their findings underscore the importance of monitoring regional prescribing trends and of targeting interventions to ensure communities at risk have the proper resources to respond to the opioid overdose epidemic. As part of the federal effort to address these areas of significance, the US Department of Health and Human Services (HHS) has declared a public health emergency and has launched a 5-point opioid strategy.

The HHS strategy includes (1) better addiction prevention, treatment, and recovery services; (2) better data; (3) better pain management; (4) better targeting of overdose reversing drugs; and (5) better research. As part of a multifaceted response, HHS has this year invested more than $2 billion in opioid-specific funding to states and communities through Substance Abuse and Mental Health Services Administration (SAMHSA) and Health Resources and Services Administration grants; provided implementation support for the CDC Guideline for Prescribing Opioids for Chronic Pain, including the enhanced integration and use of prescription drug monitoring programs; and developed a collaborative research effort through the National Institutes of Health to prevent and treat opioid misuse and opioid use disorder (OUD).

Guy et al report in this issue of JAMA Internal Medicine that the rate of opioid prescribing decreased in 2015 through 2017, although they acknowledge that current opioid prescribing is still almost three times as high as it was in 1999. The authors emphasize the importance of providing evidence-based resources to prescribers, such as the CDC Guideline to improve opioid prescribing practices. Consistent with this emphasis, HHS recently released several resources targeted to both prescribers and the communities in which they serve.

In September 2018, the Office of the Surgeon General, together with SAMHSA, released Facing Addiction in America: The Surgeon General’s Spotlight on Opioids and a digital postcard. Both resources call for a cultural shift in the way people think and talk about the opioid crisis and recommend actions that can prevent and treat opioid misuse and promote recovery.

In addition, HHS also published a comprehensive strategy document detailing 72 independent focus areas to implement the initial 5-point strategy. Finally, HHS recently published a notice in the Federal Register from the Pain Management Best Practices Inter-Agency Task Force. The notice asks for public comments to its draft recommendations to inform further guideline development, research, and education. There is some good news to report: Since January 2017, the amount of morphine milligram equivalents prescribed has declined 19.4%, the number of patients receiving buprenorphine for medication-assisted treatment has increased 21%, and monthly prescriptions for naloxone have increased 368%. And, according to the National Survey on Drug Use and Health, the number of Americans reported to be misusing pain relievers has significantly decreased.